EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

CAFs and Endocrine Therapy Resistance in Hormone Receptor-Positive Breast Cancer

Amalia A Sofianidi iD, Vaia K Stafyla, Flora Zagouri

International Journal of Molecular Sciences · 21.05.2026 · 27 (10) · 4633

DOI: 10.3390/ijms27104633 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 21.05.2026. Verfasst von Amalia A Sofianidi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Unit, Aretaieion University Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece. Hauptthemen laut MEDLINE: Breast Neoplasms, Cancer-Associated Fibroblasts, Drug Resistance, Neoplasm, Antineoplastic Agents, Hormonal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of endocrine resistance represents a major obstacle when treating hormone receptor-positive breast cancer. The tumor microenvironment (TME), represented by cancer-associated fibroblasts (CAFs) in this context, has recently been proposed as a key mediator significantly contributing to resistance against currently available endocrine therapies. The exact mechanisms behind this interaction are not fully understood; specific breast CAF subtypes have been linked to it, such as CAFs lacking the expression of the glycoprotein CD146 or maintaining the expression of CD63. Other proposed mechanisms include signaling pathways aberrantly activated in CAFs, epigenetic modifications mainly in the form of long non-coding RNAs (lncRNAs) and microRNAs (miRNAs), and paracrine signaling, all limiting endocrine modulation effectiveness. Strategies aiming to simultaneously target CAFs and endocrine signaling in luminal breast cancer are currently being developed. Fibroblast growth factor receptor (FGFR) targeting in combination with endocrine inhibition has already entered the clinical trial landscape. However, CAFs are a highly diverse and heterogeneous cell population, making their targeting complex and difficult to implement in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCancer-Associated FibroblastsDrug Resistance, NeoplasmAntineoplastic Agents, HormonalHumansFemaleTumor MicroenvironmentSignal TransductionAnimalsReceptors, EstrogenGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

CAFsbreast cancercancer-associated fibroblastsendocrine resistanceluminal

Substanzen

Antineoplastic Agents, HormonalReceptors, Estrogen

Autor:innen und Institutionen

  • Oncology Unit, Aretaieion University Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
  • 4th Department of Surgery, Attiko Hospital, School of Medicine, National and Kapodistrian University of Athens, 12462 Athens, Greece.

ORCID-Profile: Amalia A Sofianidi

Zitieren

APA

Sofianidi, A. A., Stafyla, V. K., & Zagouri, F. (2026). CAFs and Endocrine Therapy Resistance in Hormone Receptor-Positive Breast Cancer. International Journal of Molecular Sciences, 27(10), 4633. https://doi.org/10.3390/ijms27104633

Vancouver

Sofianidi AA, Stafyla VK, Zagouri F. CAFs and Endocrine Therapy Resistance in Hormone Receptor-Positive Breast Cancer. International Journal of Molecular Sciences. 2026;27(10):4633. doi:10.3390/ijms27104633

BibTeX
@article{Sofianidi2026,
  author = {Sofianidi, Amalia A and Stafyla, Vaia K and Zagouri, Flora},
  title = {CAFs and Endocrine Therapy Resistance in Hormone Receptor-Positive Breast Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {10},
  pages = {4633},
  doi = {10.3390/ijms27104633}
}
Kostenlos starten →